ARTICLE | Finance

CRISPR speculation

Speculation on what’s behind climbing CRISPR stocks

March 16, 2018 9:10 PM UTC

CRISPR companies have gained a collective $1.9 billion in market cap this quarter and two investors who spoke with BioCentury believe the run-up is primarily due to M&A speculation following the acquisitions of CAR T companies Kite Pharma Inc. and Juno Therapeutics Inc.

Since Dec. 31, CRISPR Therapeutics AG (NASDAQ:CRSP) has added $28.29 to $51.77 (120%), Intellia Therapeutics Inc. (NASDAQ:NTLA) has gained $5.39 to $24.61 (28%) and Editas Medicine Inc. (NASDAQ:EDIT) rose $7.29 (24%) to $38.02. ...